11 research outputs found
Pohjoissuomalaisten BRCA1/2-alttiusmutaation kantajanaisten syöpĂ€seulonta:takautuva seurantatutkimus vuosilta 1992â2016
TiivistelmÀ
JOHDANTO: Oulun yliopistollisen sairaalan perinnöllisyyspoliklinikan ja gynekologisen onkologian yhteisprojektina on ollut 1990-luvulta lÀhtien tavoittaa perinnöllistÀ rinta- ja munasarjasyöpÀalttiutta kantavia sukuja. Selvitimme BRCA1/2-alttiusmutaation toteamisen jÀlkeen kantajanaisten seurantatapahtumat.
MENETELMĂT: Tutkimme vuosina 1992â2016 alttiusmutaatiovastauksen saaneiden naisten mutaatiokirjoa, syöpĂ€sairastavuutta, seurantaa ja riskiĂ€ pienentĂ€viĂ€ toimenpiteitĂ€ Pohjois-Suomessa. Tarkemmat tiedot hankittiin henkilöistĂ€, jotka eivĂ€t olleet sairastaneet rinta- tai munasarjasyöpÀÀ ennen mutaatiovastausta. Tutkimus toteutettiin takautuvana rekisteritutkimuksena, jonka aineisto kerĂ€ttiin sairauskertomuksista.
TULOKSET: BRCA1-mutaatio oli 63 naisella (54 %) ja BRCA2-mutaatio 54:llÀ (46 %). Tarkemmin tarkastelluista henkilöistÀ valtaosa osallistui seurantatutkimuksiin. Mutaatiovastauksen jÀlkeen kuudella todettiin rintasyöpÀ ja kahdella munasarjasyöpÀ. RiskiÀ pienentÀvÀ munasarjojen poistoleikkaus oli mastektomiaa suositumpi.
PĂĂTELMĂT: Tutkimus on ensimmĂ€inen pohjoissuomalaisia BRCA1/2-sukuja kartoittava julkaisu. Suurin osa alttiusmutaatioista oli perustajamutaatioita. Seurantojen toteutuminen vaihteli paljon, mutta on sittemmin yhtenĂ€istynyt kansallisten suositusten ansiosta
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes
Abstract
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a major regulator of the oxidative stress response and it is negatively regulated by Kelch-like ECH-associated protein 1 (Keap1). The Keap1âNrf2 axis has a fundamental role in carcinogenesis. In previous studies, the widely used diabetes drug metformin has appeared to have a critical role in the regulation of Nrf2 function. In this study, we assessed the expression of Nrf2 and Keap1 immunohistochemically in 157 patients with type 2 diabetes who underwent breast cancer surgery with curative intent. In total, 78 (49.7%) of these patients were taking metformin alone or combined with other oral anti-diabetic medication at the time of breast cancer diagnosis. We found that high-level cytoplasmic Nrf2 expression predicted dismal overall survival and breast cancerâspecific survival, but only in the patients who were not taking metformin at the time of diagnosis. Similarly, low-level nuclear Keap1 expression had an adverse prognostic value in terms of overall survival and breast cancerâspecific survival in patients without metformin. On the other hand, high-level nuclear Keap1 expression was associated with prolonged overall survival and breast cancerâspecific survival. The results may be explained in terms of non-functioning or displaced Keap1, although more mechanistic pre-clinical and prospective clinical studies are warranted
Immunological markers of Chlamydia trachomatis infection in epithelial ovarian cancer
Abstract
Background/Aim: Pelvic inflammatory disease (PID) is a risk factor for epithelial ovarian cancer (EOC). Chlamydia trachomatis infection, a major cause of PID, may persist in some women. Serum IgG antibodies to chlamydial TroA and HtrA are more common in ascending or repeat chlamydial infection than in uncomplicated infection. The aim of this study was to explore the role of C. trachomatis infection in EOC by analyzing chlamydial TroA, HtrA and major outer membrane protein (MOMP) IgG serum antibody responses.
Patients and Methods: The study is based on the review of Oulu University Hospital medical records of 162 women diagnosed with EOC between March 2008 and May 2018. Serum IgG antibody responses to recombinant C. trachomatis TroA, HtrA and MOMP were analyzed using enzyme-linked immunoassay. Complete response to the first line therapy and the three-year survival were the study endpoints.
Results: Altogether, 16.7%, 11.1% and 12.3% women were C. trachomatis TroA, HtrA and MOMP IgG positive, respectively. Women with these antibodies were more likely to have a complete response to the first-line treatment, compared to women without these antibodies (63.0% vs. 34.1% for TroA IgG, 50.0% vs. 37.5% for HtrA IgG and 50% vs. 37.3% for MOMP IgG, respectively). The presence of these antibodies predicted better three-year survival.
Conclusion: Women with EOC and positive markers of persistent C. trachomatis infection have better response to the first-line treatment and seem to have better three-year survival
The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study
Background: Use of metformin and statins have been associated with improved prognosis of colon cancer (CC) in patients with type 2 diabetes (T2D). We examined the survival from CC in relation to the use of metformin, other oral antidiabetic medications (ADM), insulin, and statins in T2D patients. Materials and Methods: A cohort (n = 2252) of persons with pre-existing T2D diagnosed with incident CC between 1998 and 2011 was identified from several Finnish registers. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of ADM and statins before the CC diagnosis. Cox models were also fitted for mortality in relation to post-diagnostic use of the medications treating these as time-dependent exposures, and starting follow-up 1Â year after the CC diagnosis Results: Pre- and post-diagnostic metformin use was weakly associated with the risk of CCârelated death (HR.75; 95% CI.58-.99, and HR.78; 95% CI.54-1.14, respectively) compared to the use of other oral ADMs. Pre- and post-diagnostic statin use predicted a reduced risk of CCârelated death (HR.83; 95% CI.71-.98, and HR.69; 95% CI.54-.89, respectively). Conclusion: Additional evidence was found for use of statins being associated with an improved survival from CC in patients with pre-existing T2D, but for metformin use the evidence was weaker.publishedVersionPeer reviewe
The association of metformin, other antidiabetic medications and statins on the prognosis of rectal cancer in patients with type 2 diabetes:a retrospective cohort study
Abstract
Metformin and statin use have been associated with an improved prognosis for colorectal cancer in persons with type 2 diabetes (T2D). Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design. We identified 1271 eligible patients with T2D and incident RC between 1998 and 2011 from the Diabetes in Finland (FinDM) database. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of antidiabetic medication (ADM) and statins before the RC diagnosis and for post-diagnostic use in a time-dependent exposure manner. No sufficient evidence was found for either pre- or post-diagnostic metformin use and RC mortality (HR 0.96, 95% CI 0.67â1.38, and 0.70, 95% CI 0.45â1.10, respectively) when compared to other oral ADMs. Both pre- and post-diagnostic statin use appeared to be inversely associated with mortality from RC (HR 0.77 95% CI 0.63â0.94, and 0.57, 95% CI 0.42â0.78, respectively). Our study was inconclusive as to the association of metformin use with the prognosis of RC, but statin use was found to predict reduced mortality, both from RC and from other causes of death in persons with T2D
Association of metformin, other antidiabetic medications, and statins with incidence of colon cancer in patients with type 2 diabetes
Abstract
Background: Metformin and statins may have anticancer effects, with plausible cellular mechanisms. However, the association of these agents with the risk of colorectal cancer is unclear.
Patients and Methods: This was a retrospective cohort study on a large population (N = 316,317) of patients with type 2 diabetes. Data were obtained from the Diabetes in Finland database (FinDM). In a full cohort analysis, hazard ratios (HRs) with their 95% confidence intervals (CIs) for ever use versus never use were estimated using a multiple Poisson regression model. A nested caseâcontrol design within the cohort was used to examine the association of colon cancer (CC) with the defined daily dose of medication. The data were analyzed by conditional logistic regression. The analyses were adjusted for the patientâs age, sex, and duration of diabetes.
Results: In total, 1351 CC cases were diagnosed during 1996â2011. The results revealed insufficient evidence for an association between metformin (HR, 1.01; 95% CI, 0.90â1.14), other oral antidiabetic medications (HR, 1.05; 95% CI, 0.93â1.19), insulin (HR, 1.02; 95% CI, 0.86â1.22), or statins (HR, 0.94; 95% CI, 0.84â1.05) and the incidence of CC in the full cohort analysis. The results from the caseâcontrol study were similar, with no consistent trend in the incidence of CC according to the cumulative dose of metformin or the other studied medications.
Conclusion: This study found insufficient evidence for an association between metformin, insulin, other oral type 2 diabetes medications, or statins and the incidence of CC
Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes
Abstract
Purpose: To address the possible association between the use of metformin, other forms of antidiabetic medication (ADM) and statins with the incidence of breast cancer in women with type 2 diabetes (T2D).
Methods: Data were collected from a Finnish nationwide diabetes database (FinDM). The study cohort consisted of women diagnosed with T2D in 1996â2011 in Finland. In full-cohort analysis, Poisson regression was used to estimate hazard ratios (HRs) in relation to use of metformin, insulin, other forms of oral ADM and statins. In nested caseâcontrol analysis, up to 20 controls were matched for age and duration of diabetes to each case of breast cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different forms of ADM, and statins.
Results: 2300 women were diagnosed with breast cancer during follow-up. No difference in breast cancer incidence was observed between metformin users [HR 1.02, 95% confidence interval (CI) 0.93â1.11] or statin users (HR 0.97, 95% CI 0.89â1.05) compared with non-users. In nested caseâcontrol analysis the results were similar. Use of insulin (HR 1.18, 95% CI 1.03â1.36) was associated with a slightly increased incidence of breast cancer.
Conclusions: No evidence of an association between the use of metformin or statins and the incidence of breast cancer in women with T2D was found. Among insulin users, a slightly higher incidence of breast cancer was observed
Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes
Abstract
Objective: To gain further evidence of an association between the incidence of endometrial cancer (EC) and the use of metformin, other antidiabetic medication (ADM) and statins in women with type 2 diabetes (T2D).
Methods: A retrospective cohort of 92,366 women with newly diagnosed T2D was obtained from a diabetes register (FinDM). 590 endometrioid ECs were observed during the follow-up time. Poisson regression was utilized to estimate the hazard ratios (HRs) with 95% confidence intervals (95% CIs) of the endometrioid EC in relation to the use of metformin, other oral ADM, insulin and statins. Nested case-control analyses were performed, where up to 20 controls were matched for age and duration of DM for each EC case. The HRs were estimated by conditional logistic regression for never/ever and cumulative use of different forms of ADM and statins.
Results: In the case-control analyses the use of metformin (HR 1.24, 95% CI 1.02â1.51) and other oral ADM (HR 1.25, 95% CI 1.04â1.50) was associated with an increased incidence of endometrioid EC compared to no ADM use. No difference was observed between metformin users and those using other oral ADMs. The use of statins was inversely related to the incidence of endometrioid EC (HR 0.78, 95% CI 0.65â0.94). Results from the full cohort analysis supported this finding.
Conclusions: In our study the use of metformin or other oral forms of ADM was not associated with a lowered risk of endometrioid EC in women with T2D. Instead statins were observed to be inversely associated with endometrioid EC in this population
Antidiabetic medication, statins and the risk and prognosis of non-endometrioid endometrial cancer in women with type 2 diabetes
Abstract
Aim: To determine the incidence and prognosis of non-endometrioid endometrial cancer (EC) in relation to the use of metformin, other antidiabetic medication (ADM) and statins in patients with type 2 diabetes (T2D).
Materials and Methods: In order to analyze the incidence and prognosis of non-endometrioid EC, two cohorts were obtained from a nationwide diabetes database (FinDM); 57 non-endometrioid ECs were observed in a cohort of 92,366 women with newly-diagnosed T2D during the follow-up (1996 to 2011) to assess the incidence, and a retrospective cohort of 105 women with T2D diagnosed with non-endometrioid EC (1998 to 2011) was used to estimate cumulative mortality from EC and other causes of death. Hazard ratios (HRs) with 95% confidence intervals (CIs) for EC incidence were estimated in the full-cohort analysis and in the nested caseâcontrol analysis, matched for age and duration of T2D. Cumulative mortality was estimated by using the AalenâJohansen estimator. Cause-specific mortality rates were analyzed by using Cox models regarding the pre-diagnostic use of different forms of ADM and statins.
Results: In the nested caseâcontrol analysis, the use of metformin was not associated with the risk of non-endometrioid EC (HR=1.09, 95% CI=0.59â2.00), whereas statin use was associated with a lower risk (HR=0.47, 95% CI=0.26â0.84). The results from the full-cohort analysis supported these findings. Mortality from non-endometrioid EC was not different between users of metformin and other types of oral ADM (HR=1.56, 95% CI=0.40â6.07) but was observed to be lower in statin users (HR=0.41, 95% CI=0.20â0.82).
Conclusions: Our findings were inconclusive regarding the association of metformin with the risk and prognosis of non-endometrioid EC. However, statin use was associated with a lower incidence and mortality from this disease
The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes:a cohort and nested caseâcontrol study
Abstract
Objective: To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D).
Design: A retrospective cohort study and nested caseâcontrol study.
Setting: The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers.
Population: A cohort of 137 643 women over 40 years old and diagnosed with T2D during 1996â2011 in Finland.
Methods: In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral antiâdiabetic medication or statins. In the nested caseâcontrol analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration of T2D.
Main outcome measure: Incidence of ovarian cancer.
Results: In all, 303 women were diagnosed with ovarian cancer during the follow up. Compared with other forms of oral antiâdiabetic medication, metformin (HR 1.02, 95% CI: 0.72â1.45) was not found to be associated with the incidence of ovarian cancer. Neither was there evidence for statins to affect the incidence (HR 0.99, 95% CI: 0.78â1.25). In nested caseâcontrol analysis the results were essentially similar.
Conclusions: No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in women with T2D was found.
Tweetable abstract: No evidence found for metformin or statins reducing the incidence of ovarian cancer